Anesthesiology and Critical Care Medicine, Stanford University School of Medicine, Stanford, California, USA.
Anesthesiology & Perioperative Medicine, Penn State Health Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
Reg Anesth Pain Med. 2021 Apr;46(4):298-304. doi: 10.1136/rapm-2020-102017. Epub 2021 Feb 8.
There has been a surge in interest in radiofrequency ablation (RFA) of the genicular nerves over the past decade, with wide variability in selection, technique and outcomes. The aim of this study is to determine factors associated with treatment outcome.
We retrospectively evaluated the effect of 23 demographic, clinical and technical variables on outcomes in 265 patients who underwent genicular nerve RFA for knee pain at 2 civilian and 1 military hospital. A primary outcome was designated as a 30% decrease in average knee pain score lasting at least 3 months without cointerventions.
The overall rate of a positive response was 61.1% (95% CI 55.2% to 67.0%). In univariable analysis, larger electrode size (p=0.01), repeated lesions (p=0.02), having80% pain relief during the prognostic block (p=0.02), not being on opioids (p=0.04), having no coexisting psychiatric condition (p=0.02), having a lower baseline pain score (p=0.01) and having >3 nerves targeted (p=0.02) were associated with a positive outcome. In multivariate logistic analysis, being obese (OR 3.68, 95% CI 1.66 to 8.19, p=0.001), not using opioids (OR 0.35, 95% CI 0.16 to 0.77, p=0.009), not being depressed (OR 0.29, 95% CI 0.10 to 0.82, p=0.02), use of cooled RFA (OR 3.88, 95% CI 1.63 to 9.23, p=0.002) and performing multiple lesions at each neural target (OR 15.88, 95% CI 4.24 to 59.50, p<0.001) were associated with positive outcome.
We identified multiple clinical and technical factors associated with treatment outcome, which should be considered when selecting patients for RFA treatment and in the design of clinical trials.
在过去十年中,对关节神经射频消融(RFA)的兴趣激增,选择、技术和结果存在广泛差异。本研究旨在确定与治疗结果相关的因素。
我们回顾性评估了 23 项人口统计学、临床和技术变量对 265 名在 2 家民用医院和 1 家军事医院接受膝关节神经 RFA 治疗膝关节疼痛患者的结局的影响。主要结果是在没有联合干预的情况下,平均膝关节疼痛评分至少下降 30%且持续至少 3 个月。
阳性反应的总体率为 61.1%(95%CI 55.2%至 67.0%)。在单变量分析中,较大的电极尺寸(p=0.01)、重复病变(p=0.02)、在预测性阻滞中达到 80%疼痛缓解(p=0.02)、未使用阿片类药物(p=0.04)、无并存精神疾病(p=0.02)、基线疼痛评分较低(p=0.01)和目标神经≥3 支(p=0.02)与阳性结果相关。多变量逻辑分析显示,肥胖(OR 3.68,95%CI 1.66 至 8.19,p=0.001)、不使用阿片类药物(OR 0.35,95%CI 0.16 至 0.77,p=0.009)、不抑郁(OR 0.29,95%CI 0.10 至 0.82,p=0.02)、使用冷却 RFA(OR 3.88,95%CI 1.63 至 9.23,p=0.002)和在每个神经靶标进行多次病变(OR 15.88,95%CI 4.24 至 59.50,p<0.001)与阳性结果相关。
我们确定了与治疗结果相关的多个临床和技术因素,在为 RFA 治疗选择患者和设计临床试验时应考虑这些因素。